Daniele Minardi1, Guendalina Lucarini2, Giulio Milanese3, Roberto Di Primio2, Rodolfo Montironi4, Giovanni Muzzonigro3. 1. Dipartimento di Scienze Cliniche e Specialistiche-Sezione di Urologia, Università Politecnica delle Marche-Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy. Electronic address: d.minardi@gostec.net. 2. Dipartimento di Scienze Cliniche e Molecolari-Sezione di Istologia, Università Politecnica delle Marche, Ancona, Italy. 3. Dipartimento di Scienze Cliniche e Specialistiche-Sezione di Urologia, Università Politecnica delle Marche-Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy. 4. Dipartimento di Scienze Biomediche e Sanità Pubblica-Sezione di Patologia e Istopatologia, Università Politecnica delle Marche-Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy.
Abstract
INTRODUCTION: BRCA1-associated protein 1 (BAP1) is a gene situated on chromosome 3p in a region that is deleted in more than 90% of renal cell carcinomas (RCCs). In the present study, we studied BAP1 immunohistochemical expression in a large series of conventional clear cell RCCs (ccRCCs) treated with radical nephrectomy; we assessed the prognostic value of their expression in terms of patients׳ survival at long-term follow-up. MATERIALS AND METHODS: A total of 154 consecutive patients with ccRCC were selected from a prospective database and considered for the study purpose; all patients were treated with radical nephrectomy and lymphadenectomy at our Institute of Urology between 1983 and 1985. The features considered in this study were tumor size, grade and stage, vascular and capsular invasion, incidence of metastasis, and patient-specific survival; all these parameters were correlated with immunohistochemical cytoplasmic and nuclear expression of BAP1 in tumoral tissue. RESULTS: Median follow-up was 196.18 months and median survival was 125.34 months. Nuclear BAP1 expression showed a high frequency of loss in tumoral cells; nuclear BAP1-negative tumors had higher tumor size, higher Fuhrman grade, and higher stage, a greater amount of vascular and capsular invasion and a higher incidence of metastases. In multivariate analysis, pathological stage and nuclear BAP1 expression resulted independent prognostic factors. CONCLUSION: We have demonstrated that nuclear BAP1 expression is a marker of prognosis in ccRCC, having an influence on cancer-specific survival. The clinical importance for BAP1 will be realized with the identification and application of targeted therapies and with individualized approaches in the adjuvant setting or in the metastatic setting or in both the settings.
INTRODUCTION:BRCA1-associated protein 1 (BAP1) is a gene situated on chromosome 3p in a region that is deleted in more than 90% of renal cell carcinomas (RCCs). In the present study, we studied BAP1 immunohistochemical expression in a large series of conventional clear cell RCCs (ccRCCs) treated with radical nephrectomy; we assessed the prognostic value of their expression in terms of patients׳ survival at long-term follow-up. MATERIALS AND METHODS: A total of 154 consecutive patients with ccRCC were selected from a prospective database and considered for the study purpose; all patients were treated with radical nephrectomy and lymphadenectomy at our Institute of Urology between 1983 and 1985. The features considered in this study were tumor size, grade and stage, vascular and capsular invasion, incidence of metastasis, and patient-specific survival; all these parameters were correlated with immunohistochemical cytoplasmic and nuclear expression of BAP1 in tumoral tissue. RESULTS: Median follow-up was 196.18 months and median survival was 125.34 months. Nuclear BAP1 expression showed a high frequency of loss in tumoral cells; nuclear BAP1-negative tumors had higher tumor size, higher Fuhrman grade, and higher stage, a greater amount of vascular and capsular invasion and a higher incidence of metastases. In multivariate analysis, pathological stage and nuclear BAP1 expression resulted independent prognostic factors. CONCLUSION: We have demonstrated that nuclear BAP1 expression is a marker of prognosis in ccRCC, having an influence on cancer-specific survival. The clinical importance for BAP1 will be realized with the identification and application of targeted therapies and with individualized approaches in the adjuvant setting or in the metastatic setting or in both the settings.
Authors: Svenja Bihr; Riuko Ohashi; Ariane L Moore; Jan H Rüschoff; Christian Beisel; Thomas Hermanns; Axel Mischo; Claudia Corrò; Jörg Beyer; Niko Beerenwinkel; Holger Moch; Peter Schraml Journal: Neoplasia Date: 2019-01-16 Impact factor: 5.715
Authors: Stefan Steurer; Lara Schwemmer; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Till S Clauditz; Andreas M Luebke; Ronald Simon; Guido Sauter; Jakob Izbicki; Cornelia Schroeder; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Alexander Haese; Markus Graefen; Cosima Göbel; Sören Weidemann; Patrick Lebok; David Dum; Christoph Fraune; Sarah Minner; Jan Meiners Journal: Oncotarget Date: 2019-12-24